

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	Hickinson	Filed	Herewith
Application No.	Not yet assigned	Attorney Docket No.	100873-1P US
PCT Application No.	PCT/GB2003/004655	Examiner	Not yet assigned
Title	ASSAY FOR THE SCREENING OF COMPOUNDS ACTING THROUGH ERBB-2		


Mail Stop PCT
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant(s), wish to call the Examiner's attention to and make of record the references cited on the attached form(s) PTO-1449. All of the cited references were listed on the International Search Report, a copy of which is enclosed herewith for the convenience of the Examiner. Copies of the references are not being provided herewith because it is believed they were previously forwarded to the USPTO by the International Patent Bureau. Applicants are also enclosing a copy of the International Examination Report.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form.

Respectfully submitted,



Name. Christine McCormack
Reg. No. Limited Recognition Under 37
CFR §10.9(b)
Phone No. 1 781 839 4693

Dated: April 20, 2005

Enclosures: Form 1449
International Search Report
International Examination Report

INFORMATION DISCLOSURE STATEMENT Form PTO-1449	Application Details	
	First Named Inventor	Daniel Mark Hickinson
	Filing Date	Herewith
	Application Serial No.	Not yet assigned
	Examiner Name	Not yet assigned
	Group Art Unit	Not yet assigned
	Attorney Docket No.	100873-1P US

U.S. PATENT DOCUMENTS							
Examiner Initials	Desig. ID	Document Number	Publication Date	Name	Class	Sub Class	Filing Date if Appropriate
	AA	US 5 804 396 A	8 September 1998				

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Sub Class s	Filing Date	English Language
								Y
	AB	WO 02 09684 A	7 February 2002					Y
	AC	WO 02 41828 A	30 May 2002					Y
	AD	WO 03 061559 A	31 July 2003					Y

OTHER DOCUMENTS (include Author, Title, Date and Place of Publication)		
Examiner Initials	Desig. ID	Document
	AE	RAM G ET AL : "Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification" Cell Growth And Differentiation, vol . 11, no . 3, March 2000 (2000-03), pages 173-183.

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	AF	RAM ET AL : "Phosphatidylinositol 3-kinase recruitment by p185-erb-2 and erb-3 is potently induced by neu differentiation factor/hereregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erb-2 gene amplification" cell growth and differentiation, The Association, Philadelphia, PA, US, vol . 7, no . 5, May 1996 (1996-05), pages 551-561.
	AG	RAM ET AL : "Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine-phosphorylated p185-erbB-2" Molecular Carcinogenesis, vol . 15, no . 3, 1996, pages 227-238.
	AH	RAM ET AL : "Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells" Journal Of Cellular Physiology, vol . 183, no . 3, June 2000 (2000-06), pages 301-313.
	AI	LEWIS ET AL : "Growth regulation of human breast and ovarian tumor cells by heregulin : evidence for the requirement of erbb2 as a critical component in mediating heregulin responsiveness" Cancer Research, American Association For Cancer Research, Baltimore, MD, US, vol . 56, 15 March 1996 (1996-03-15), pages 1457-1465.
	AJ	MENDELSON ET AL : "The EGF receptor family as targets for cancer therapy" oncogene, basingstoke, hants, GB, vol . 19, no. 56, 2000, pages 6550-6565.

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

*EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.